Skoulidis and colleagues recently demonstrated that KRAS-mutant lung adenocarcinomas harboring LKB1 co-mutations are associated with lower progression free survival (PFS) and OS to Protein death 1 (PD-1) blockade, thus suggesting a role of LKB1 in primary resistance to this class of drugs [41]. Here, STK11 is linked to lung adenocarcinoma.